Abstract
Purpose
The objective of this investigation is to explore the capability of baseline 18F-FDG PET/CT radiomics to predict the prognosis of diffuse large B-cell lymphoma (DLBCL) with extranodal involvement (ENI).
Methods
126 patients diagnosed with DLBCL with ENI were included in the cohort. The least absolute shrinkage and selection operator (LASSO) Cox regression was utilized to refine the optimum subset from the 1328 features. Cox regression analyses were employed to discern significant clinical variables and conventional PET parameters, which were then employed with radiomics score to develop combined model for predicting both progression-free survival (PFS) and overall survival (OS). The fitness and the predictive capability of the models were assessed via the Akaike information criterion (AIC) and concordance index (C-index).
Results
62 patients experienced disease recurrence or progression and 28 patients ultimately died. The combined model exhibited a lower AIC value compared to the radiomics model and SDmax/clinical variables for both PFS (507.101 vs. 510.658 vs. 525.506) and OS (215.667 vs. 230.556 vs. 219.313), respectively. The C-indices of the combined model, radiomics model, and SDmax/clinical variables were 0.724, 0.704, and 0.615 for PFS, and 0.842, 0.744, and 0.792 for OS, respectively. Kaplan––Meier curves showed significantly higher rates of relapse and mortality among patients classified as high-risk compared to those classified as low-risk (all P < 0.05).
Conclusions
The combined model of clinical variables, conventional PET parameters, and baseline PET/CT radiomics features demonstrates a higher accuracy in predicting the prognosis of DLBCL with ENI.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is an invasive neoplasm derived from mature B cells and represents the most prevalent type of lymphatic malignancy [1]. DLBCL predominantly originates in lymph nodes, with some cases exhibiting secondary spread to extranodal organs, including the gastrointestinal (GI) tract, central nervous system (CNS), bones, lungs, and liver [2]. Approximately one-third of DLBCL patients may also present with primary extranodal involvement (ENI) [3]. DLBCL with extranodal presentation exhibits genetic and clinical distinctions from nodal DLBCL, negatively impacting the prognosis of patients [2, 4,5,6]. The prognostic significance of multiple ENI has been acknowledged and integrated into the International Prognostic Index (IPI), which stands as one of the most prevalent clinical prognostic models [7]. Additionally, the National Comprehensive Cancer Network-IPI (NCCN-IPI) underscores the importance of disease manifestation at distinct extranodal locations such as the bone marrow, CNS, liver/GI tract, or lung [8]. According to existing literature [4], patients with multiple ENI exhibited a notable decrease in the overall response rate (75.5% vs. 89.3%) and the 2 year overall survival rate (61.8% vs. 81.3%) when compared to individuals without ENI, following routine first-line treatment with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. The results of a study demonstrate that the first-line treatment regimen zanubrutinib with R-CHOP (ZR-CHOP) yields superior efficacy and a longer duration of remission for high-risk DLBCL patients with ENI, coupled with tolerable safety profiles [9]. Hence, the proactive identification of DLBCL with ENI at a heightened risk of recurrence or mortality holds significant value. This proactive strategy can provide crucial assistance to clinicians in formulating personalized treatment plans.
18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) serves a crucial function in evaluating the prognosis of DLBCL with ENI. A recent study has indicated that the total metabolic tumor volume (TMTV) of ENI significantly influences the prognosis of DLBCL. Within the overall TMTV of DLBCL lesions, extranodal TMTV may have a more substantial impact on prognosis compared to nodal TMTV [10]. This finding underscores the essential contribution of 18F-FDG PET/CT in revealing the heterogeneity of DLBCL and formulating personalized treatment strategies. Nonetheless, relying solely on PET parameters does not comprehensively encompass the morphological and metabolic features of the lesions. Baseline PET radiomics, established by analyzing these features to extract deeper insights, have emerged as crucial independent prognostic factors for DLBCL [11,12,13,14]. Notably, there is currently relatively limited research on radiomics predicting the prognosis of DLBCL with ENI.
Therefore, the objective of this investigation is to delve deeper into the capability of radiomics to predict the prognosis of DLBCL with ENI.
Materials and methods
Study population
This study, approved by the institutional ethics review board under No. 2022KY288, involved a retrospective analysis of patients diagnosed with new-onset DLBCL in our department between October 2013 and June 2022. The requirement for obtaining written informed consent was waived by the institutional review committee. The inclusion criteria for the study comprised the following: (1) age 18 years or older, (2) histologically confirmed diagnosis of DLBCL, (3) presenting extranodal involvement on baseline 18F-FDG PET/CT scans, and (4) receiving initial treatment with R-CHOP(-like). Individuals were excluded if they had incomplete clinical data or a documented history of prior cancer.
A cohort comprised 126 patients diagnosed with DLBCL with extranodal involvement (ENI), consisting of 74 men and 52 women. The patients’ average age was 56.80 ± 14.20 years, ranging from 23 to 84 years. Patient selection process is illustrated in Supplementary Fig. 1 through a flowchart. Several clinical characteristics were documented, encompassing age, gender, number and specific sites of ENI, performance status, B symptoms, pathological type, serum lactate dehydrogenase (LDH) level, and serum β2-microglobulin (β2-MG) level. The NCCN-IPI was computed using a method that had been established previously [8].
Follow-up assessments occurred post-treatment and continued until October 2023, ensuring at least 16 months of follow-up or until mortality. We have categorized the various treatment modalities administered to patients in this study. Supplementary Table 1 summarizes the treatment approaches. This study examined the prognosis of DLBCL, with 5-year progression-free survival (PFS) and 5-year overall survival (OS) as the main focus. PFS represented the time from initial diagnosis to disease recurrence, progression, or mortality. Correspondingly, OS was measured from diagnosis to mortality.
PET/CT examination
The PET/CT examinations was conducted using either PHILIPS GEMINI GXL16 (45 patients, 35.7%) or PHILIPS Vereos (81 patients, 64.3%) scanners. Prior to the injection of 18F-FDG, patients fasted for a minimum of 6 h, and their blood glucose levels needed to be below 11.1 mmol/L. Following the intravenous injection of 18F-FDG, PET/CT scans (covering the entire body) were conducted about 60 ± 5 min later. CT acquisition data were employed for attenuation correction. Supplementary Table 2 provides the detailed PET/CT image acquisition parameters.
VOI segmentation and radiomics feature extraction
Two experienced nuclear medicine physicians with over 5 years of diagnostic experience, blinded to the outcomes, used the LIFEx software (version 7.3.0; available at https://www.lifexsoft.org/) to semi-automatically delineate the volumes of interest (VOIs) in the PET images with a fixed threshold of the maximum standardized uptake value (SUVmax) ≥ 2.5 and ≥ 4.0 [15, 16].
All radiomics features from the two segmentation methods were extracted utilizing the open-source PyRadiomics, available at http://www.radiomics.io/pyradiomics.html [17,18,19]. Subsequently, to mitigate the impact of variations in size, characteristics, and distribution, the z-score method was applied to standardize the radiomics signatures. Figure 1 depicts the radiomics analysis workflow.
Feature selection and model construction
To mitigate issues of multicollinearity and overfitting, the least absolute shrinkage and selection operator (LASSO) Cox regression algorithm, employing tenfold cross-validation, was utilized to independently refine the optimum subset from the all 1328 features based on the two segmentation methods. The radiomics scores were calculated by aggregating the chosen signatures and each signature was weighted based on its corresponding LASSO coefficient.
Construction of hybrid nomograms
Conventional PET parameters of the lesions at the patient level were evaluated, including SDmax, SUVmax_T, TMTV, and total lesion glycolysis (TLG). Additionally, parameters specific to the largest lesion, such as SUVmax_B, metabolic bulk volume (MBV), and TLG_B, were also examined. SDmax was defined as the maximum separation among lesions, normalized according to the patient’s body surface area (BSA). Additionally, MBV was calculated as the metabolic volume of the largest identified lesion. The cutoff points of these parameters were determined using X-tile software (version 3.6.1, Yale University).
Univariate Cox regression analysis was employed to assess the prognostic value of clinical variables and conventional PET parameters of the lesion (at patient level and largest lesion level). Subsequently, multivariate Cox regression was employed to discern significant clinical variables and conventional PET parameters, which were then employed with radiomics score to develop combined model for predicting both PFS and OS. Hybrid nomograms were developed based on the regression coefficients of each factor that retained significant in the multivariate Cox analysis of the combined model [20].
Model performance assessment and validation
The fitness of the models was assessed via the Akaike information criterion (AIC) [21], while their predictive performance was evaluated using Harrell’s concordance index (C-index). Internal validation was performed using a bootstrap resampling technique to obtain corrected C-index values [22]. Additionally, distinctions in the area under the curve (AUC) values between radiomic models derived from two segmentation methods were analyzed using the DeLong test (MedCalc19.6.4). Subsequently, the optimal radiomics model was determined and integrated with clinical and conventional PET features to create a combined model.
Statistical analysis
All statistical analyses were conducted utilizing R statistical software (version 4.2.2) (http://www.R-project.org) and SPSS software (version 26.0, IBM). The optimum cutoff points of the radiomics score and the combined model score were determined to stratify patients into low- or high-risk groups. Survival outcomes were assessed through Kaplan–Meier analysis and compared utilizing log-rank tests. Statistical significance was determined at a P-value less than 0.05. The dependence of the models on the type of scanners was compared with the Mann–Whitney U test.
Results
Patient characteristics
The characteristics of the DLBCL with ENI were outlined in Table 1. The median follow-up duration for patients was 29.77 months (range: 4.53–111.97 months). During this period, 62 patients experienced disease recurrence or progression, and 28 patients ultimately died. The 5-year PFS rate was 51.6% (65/126), and the 5 year OS rate was 78.6% (99/126). The ENI site was most commonly observed in the bone marrow (50, 39.7%), followed by the bones (48, 38.1%), stomach (22, 17.5%), intestine (20, 15.9%), lungs (20, 15.9%), kidney/adrenal glands (18, 14.3%), skin (11, 8.7%), liver (9, 7.1%), breasts (9, 7.1%), uterus/ovaries (6, 4.8%), nasal cavity (6, 4.8%), testes (5, 4.0%), CNS (5, 4.0%), muscles (5, 4.0%), pancreas (4, 3.2%), thyroid (1, 0.8%), and heart (1, 0.8%) (Fig. 2).
Feature analysis and model establishment
The outcomes of the LASSO Cox analysis are depicted in Supplementary Fig. 2. Using the fixed thresholding method with SUVmax ≥ 2.5, a total of 8 and 4 optimal signatures were identified for predicting PFS and OS, respectively. Meanwhile, using SUVmax ≥ 4.0, a total of 6 and 8 optimal signatures were identified for predicting PFS and OS, respectively. Supplementary Table 3 provides a list of the selected features along with their corresponding coefficients.
The C-index values of the radiomics models derived from SUV ≥ 2.5 and SUV ≥ 4.0 segmentation methods were 0.693 (95% CI 0.660–0.727) and 0.704 (95% CI 0.671–0.738) for predicting PFS, and 0.742 (95% CI 0.696–0.789) and 0.744 (95% CI 0.699–0.789) for OS, respectively. No statistically significant difference in the AUC between the two radiomics models was observed for both PFS and OS (P = 0.974 and 0.957, respectively). Compared to the SUV ≥ 2.5 segmentation method, the radiomics model obtained from the SUV ≥ 4.0 segmentation method exhibited slightly better performance in predicting PFS and OS. Moreover, this method requires less manual adjustment, saving time and effort. Therefore, it will be considered as the optimal radiomics model and will be combined with clinical and conventional PET features.
For the clinical variables, we identified the number of ENI in major organs (HR = 2.265, P = 0.003) and time interval to recurrence (HR = 1.932, P = 0.005) as independent risk factors for OS, while no independent factors were found for PFS. Regarding conventional PET parameters, univariate and multivariate analysis showed that the SDmax was an independent risk predictor for both PFS (HR = 3.106, P = 0.004) and OS (HR = 4.318, P = 0.004) (Fig. 3 and Supplementary Table 4).
In the multivariate analysis of the combined model, SDmax (HR = 2.378, P = 0.030) and radiomics score (HR = 7.328, P < 0.001) emerged as independent predictors of PFS. Additionally, the number of ENI in major organs (HR = 1.978, P < 0.001), time interval to recurrence (HR = 1.769, P = 0.018), and radiomics score (HR = 2.368, P = 0.047) were recognized as predictors of OS independently (Supplementary Table 5). The hybrid nomograms provide a visual representation of the prediction outcomes and the contribution of each factor for both PFS and OS (Fig. 4).
Model performance assessment and validation
The combined model exhibited a lower AIC value compared to the radiomics model and SDmax for both PFS (507.101 vs. 510.658 vs. 525.506) and OS (215.667 vs. 230.556 vs. 219.313), respectively. For PFS, the C-indices of the combined model, radiomics model, and SDmax were 0.724 (95% CI 0.692–0.756), 0.704 (95% CI 0.671–0.738), and 0.615 (95% CI 0.590–0.641), respectively. Regarding OS, the C-indices of the combined model, radiomics model, and clinical variables were 0.842 (95% CI 0.811–0.874), 0.744 (95% CI 0.699–0.789), and 0.792 (95% CI 0.748–0.837), respectively. The findings were further validated by bootstrap resampling (n = 1000) (Supplementary Table 6).
Survival prediction and risk stratification
For predicting low or high recurrence risk, the cutoff values of the radiomics score and the combined model score were 0.10 and 1.00, respectively. Similarly, for predicting the risk of patient death, the cutoff values of the radiomics score and the combined model score were 0.16 and 1.25, respectively. In both radiomics and combined models, the Kaplan–Meier curves showed significantly higher rates of relapse and mortality among patients classified as high-risk compared to those classified as low-risk (all P < 0.05) (Fig. 5).
Scanner comparability
There were no statistically significant differences in the performance of the combined model, radiomics model, and SDmax/clinical variables when considering different scanner types different scanner types (PFS P=0.641, 0.506, and 0.836, respectively; OS P=0.897, 0.701, and 0.457, respectively).
Discussion
DLBCL with ENI represents a distinct subgroup of lymphomas associated with unique clinical and genetic characteristics, often leading to a worse prognosis compared to nodal DLBCL. Early identification of DLBCL with ENI at a higher risk of recurrence or death is crucial for clinicians to develop personalized treatment strategies and improve outcomes. Our retrospective study indicates that baseline 18F-FDG PET radiomics and hybrid nomogram may prognosticate the outcomes of DLBCL with ENI. The hybrid nomograms, which combine radiomics with clinical factors or conventional PET parameters, outperformed models based solely on clinical factors or PET parameters. This underscores the incremental prognostic value that radiomics brings to the predictive accuracy of clinical and PET parameters. To our knowledge, there is limited research on radiomics predicting the prognosis of DLBCL with ENI.
A previous study represented the first attempt to integrate radiomics with IPI to evaluate the prognostic value of baseline PET/CT in DLBCL [11]. Subsequent studies have further confirmed that PET-based radiomics enhances the prognostic predictive value of clinical factors in DLBCL [23,24,25]. These findings are consistent with our study, indicating that the combination of radiomics with conventional PET parameter (SDmax) or clinical factors (the number of ENI in major organs and time interval to recurrence) could predict 5 year PFS and 5 year OS with better goodness of fit (lower AIC) and performance (higher C-index) compared to standalone conventional PET parameter or clinical factors in DLBCL with ENI.
Whether patients with DLBCL have multiple ENI and major organ involvement have already been included in clinical prognostic models such as IPI and NCCN-IPI [7, 8]. In this study, the number of ENI in major organs was identified as an independent risk factor for OS in DLBCL with ENI, while the number of ENI sites and whether there was involvement of major organs were not independent prognostic factors for OS. None of these factors was an independent prognostic factor for PFS. In addition, the time interval to recurrence was identified as an independent predictor of OS. Particularly, when the recurrence time interval was less than 1 year, the prognosis was poorer, consistent with the viewpoint in the previous literature [26]. In our study, SDmax was identified as an independent predictor for PFS but not for OS. Other conventional PET parameters, such as TMTV and TLG, have also demonstrated no independent correlation with either PFS or OS. While another study indicated that SDmax and TMTV, reflecting tumor dissemination and its burden, served as independent prognostic indicators [27]. These parameters could be utilized to identify high-risk patients with DLBCL. The potential rationales lie in the study’s exclusive focus on DLBCL with ENI, setting it apart from other predictive models. Consequently, the study’s emphasis may be more concentrated on specific aspects of ENI, such as the affected major organs, potentially carrying greater independent significance in the prediction of overall survival. Additionally, radiomic features are closely correlated with the intratumoral metabolic heterogeneity and complexity [28]. The inclusion of radiomics variables in the combined model may exert a more pronounced impact on survival prognosis, thereby relatively diminishing the prognostic efficacy of clinical factors or conventional PET parameters.
This study compared the performance of radiomic models in predicting patient PFS and OS using two different semi-automated segmentation methods. The results showed that the SUV ≥ 4.0 segmentation method exhibited slightly better performance compared to the SUV ≥ 2.5 method, although there was no statistical difference between the two models. Moreover, this method requires less manual adjustment, saving time and effort, and has been recommended and utilized for prognostic evaluation [29, 30]. However, consensus has not yet been reached on standardized segmentation methods for computing DLBCL radiomic features, making it an ongoing focus of future studies [17]. Despite variations in data distribution among different PET/CT scanners, there were no statistically significant differences in predicting the prognosis of DLBCL with ENI. Therefore, in our study population, the scanner selection may not play a substantial role in affecting prognosis.
This study has certain limitations. It is a single-center retrospective study and lacks external validation, which may introduce selection bias, overestimate the model’s performance, and limit the generalizability of the model. In future research, further validation should be conducted in larger cohorts and prospective studies to determine the clinical applicability of these models in guiding treatment decisions for DLBCL with ENI.
Conclusions
This study explores the capability of baseline PET/CT radiomics to prognosticate the outcomes of DLBCL with ENI. The combined model incorporating clinical variables, conventional PET parameters, and radiomics features demonstrates high accuracy in prognostic prediction for DLBCL with ENI.
Data availability
The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.
References
Pon JR, Marra MA. Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma. Blood. 2016;127:181–6.
Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118:4166–72.
Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the surveillance, epidemiology and end results database. Am J Hematol. 2014;89:310–4.
Shen R, Xu PP, Wang N, Yi HM, Dong L, Fu D, et al. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin Transl Med. 2020;10: e221.
Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.
A predictive model for aggressive non-Hodgkin’s lymphoma. New england journal of medicine. 1993;329:987–94
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.
Geng H, Jia S, Zhang Y, Li J, Yang Q, Zeng L, et al. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement. Front Immunol. 2023;14:1219167.
Oiwa K, Fujita K, Lee S, Morishita T, Tsujikawa T, Negoro E, et al. Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma. Ann Hematol. 2023;102:1141–8.
Zhang X, Chen L, Jiang H, He X, Feng L, Ni M, et al. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022;49:1298–310.
Frood R, Clark M, Burton C, Tsoumpas C, Frangi AF, Gleeson F, et al. Discovery of pre-treatment FDG PET/CT-derived radiomics-based models for predicting outcome in diffuse large B-cell lymphoma. Cancers (Basel). 2022;14:1711.
Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ, et al. (18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:932–42.
Jing F, Liu Y, Zhao X, Wang N, Dai M, Chen X, et al. Baseline (18)F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma. EJNMMI Res. 2023;13:92.
Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.
Barrington SF, Zwezerijnen B, de Vet HCW, Heymans MW, Mikhaeel NG, Burggraaff CN, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62:332–7.
Hatt M, Krizsan AK, Rahmim A, Bradshaw TJ, Costa PF, Forgacs A, et al. Joint EANM/SNMMI guideline on radiomics in nuclear medicine: jointly supported by the EANM Physics Committee and the SNMMI Physics, instrumentation and data sciences council. Eur J Nucl Med Mol Imaging. 2023;50:352–75.
van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7.
Mu W, Schabath MB, Gillies RJ. Images are data: challenges and opportunities in the clinical translation of radiomics. Cancer Res. 2022;82:2066–8.
Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70.
Lu Y, Yu J, Gong W, Su L, Sun X, Bai O, et al. An immune-clinical prognostic index (ICPI) for patients with De Novo follicular lymphoma treated with R-CHOP/CHOP chemotherapy. Front Oncol. 2021;11: 708784.
Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart R, et al. Prediction of response to neoadjuvant chemotherapy and radiation therapy with baseline and restaging (18)F-FDG PET imaging biomarkers in patients with esophageal cancer. Radiology. 2018;287:983–92.
Jiang C, Li A, Teng Y, Huang X, Ding C, Chen J, et al. Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:2902–16.
Zhao S, Wang J, Jin C, Zhang X, Xue C, Zhou R, et al. Stacking ensemble learning-based [(18)F]FDG PET radiomics for outcome prediction in diffuse large B-cell lymphoma. J Nucl Med. 2023;64:1603–9.
Travaini LL, Botta F, Derenzini E, Lo Presti G, Ferrari ME, Airo Farulla LS, et al. [(18) F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma. Hematol Oncol. 2023;41:674–82.
Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139:1330–9.
Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(dagger). Ann Oncol. 2021;32:404–11.
Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton JD, Snyder A, et al. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol. 2017;72:3–10.
Driessen J, Zwezerijnen GJC, Schoder H, Drees EEE, Kersten MJ, Moskowitz AJ, et al. The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in (18)F-FDG PET scans of patients with classical Hodgkin lymphoma. J Nucl Med. 2022;63:1424–30.
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Duhrsen U, et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023;141:3055–64.
Acknowledgements
The authors thank all their coworkers involved in the study for their support and assistance.
Funding
This study was supported by the Hebei Provincial Health Committee (Grant No. 20230916), Hebei Provincial Health Committee (Grant No. 20240855) and the Hebei Province Medical Applicable Technology Tracking Project (Grant No. G2019028) in China.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation and data collection were performed by Fenglian Jing, Xinchao Zhang, Yunuan Liu, Xiaolin Chen, and Jianqiang Zhao. Data analysis was performed by Fenglian Jing, Xinchao Zhang, Xiaoshan Chen, Huiqing Yuan, Meng Dai, and Na Wang. Xinming Zhao, Zhaoqi Zhang, and Jingmian Zhang were responsible for the concept and design of the study. The first draft of the manuscript was written by Fenglian Jing and all authors commented on previous versions of the manuscript. Fenglian Jing revised it and Xinming Zhao supervised the study. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the Fourth Hospital of Hebei Medical University (No.2022KY288).
Consent to participate
The requirement of informed consent was waived.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jing, F., Zhang, X., Liu, Y. et al. Baseline 18F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma with extranodal involvement. Clin Transl Oncol (2024). https://doi.org/10.1007/s12094-024-03633-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12094-024-03633-y